← back to database
5AM Ventures
Early-stage life-science venture capital: private therapeutics, biopharmaceuticals, drug-delivery technologies and life-science instruments; company-building and internal incubation of breakthrough science.
Stage focus
Lead / follow
Specialization
Generalist / Specialist
Specialist
Latest fund size
$450M — 5AM Ventures VII, L.P.
Latest fund vintage
2022
Investing team
- Kush M Parmar, MD, PhDManaging Partner
- Andy J. SchwabManaging Partner
- Anna YaegerChief Investment Officer and Partner
- Michael CalorePartner, Head of Investor Relations
- John KellyPartner, Chief Financial Officer & Chief Operating Officer
- Deborah Palestrant, PhDPartner, Executive Chair, 4:59 Initiative
- Maggie AikenAssistant Controller
- Andrew BoothVenture Advisor
- Brian Daniels, MDVenture Partner
- John D. Diekman, PhDFounding Partner
- Max Farina, MDPrincipal
- Travis Fleming, PhDAnalyst
- Mason Freeman, MDVenture Partner
- Joshua GrassVenture Partner
- Steve Hitchcock, PhDVenture Partner
- Peter S. Kim, PhDVenture Advisor
- Elliott Levy, MDVenture Partner
- Lidia LiuSenior Research Analyst
- Joe Loscalzo, MD, PhDVenture Advisor
- Vamsi Mootha, MDVenture Advisor
- Scott M. Rocklage, PhDFounding Partner
- Paula SoteropoulosVenture Advisor
- Katie Bodner Spielberg, PhDPrincipal
- Arthur Tzianabos, PhDVenture Partner
- Joseph J. VictorVenture Advisor
- Jonathan Weissman, PhDVenture Advisor
Notable investments
January 2026: Mendra launched with an $82M Series A co-led by 5AM Ventures, OrbiMed and 8VC; official 5AM LinkedIn post confirms backing at company launch.